Moreover, CD28 co-stimulatory pathway plays key roles in modulating the tumor immune microenvironment and patients’ responses to anti–PD-L1/PD-1 therapy (Hui et al., 2017; Kamphorst et al., 2017; Duraiswamy et al., 2021). This evidence concerns the gene CD274 and neoplasm.